Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
Paul Toren(Children's Mercy Hospital), Amina Zoubeidi(Cervantes Institute)
Cited by 36
Related Papers
Targeting the PI3K/Akt pathway in prostate cancer: Challenges and opportunities (Review)
|International Journal of Oncology|2014|158
Hsp27 Promotes Insulin-Like Growth Factor-I Survival Signaling in Prostate Cancer via p90Rsk-Dependent Phosphorylation and Inactivation of BAD
|Cancer Research|2010|101
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
|Journal of Medicinal Chemistry|2011|69
RETRACTED: Hsp27 regulates EGF/β‐catenin mediated epithelial to mesenchymal transition in prostate cancer
|International Journal of Cancer|2014|67